인히비카제 테라퓨틱스(IKT)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.32 (+0.87%), 시가총액 $0.22B, 52주 최저~최고 $1.41 ~ $2.14.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The comp
인히비카제 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
인히비카제 테라퓨틱스의 현재 주가는 $2.32 (+0.87%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
인히비카제 테라퓨틱스의 시가총액은 약 $0.22B입니다.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arteria